Provided by Tiger Trade Technology Pte. Ltd.

Bristol-Myers Squibb

61.46
-0.9400-1.51%
Post-market: 61.560.1032+0.17%18:29 EDT
Volume:10.77M
Turnover:663.21M
Market Cap:125.12B
PE:13.53
High:62.61
Open:62.20
Low:61.25
Close:62.40
52wk High:68.64
52wk Low:42.52
Shares:2.04B
Float Shares:2.03B
Volume Ratio:0.76
T/O Rate:0.53%
Dividend:2.51
Dividend Rate:4.08%
EPS(TTM):4.54
EPS(LYR):3.46
ROE:46.60%
ROA:10.72%
PB:5.61
PE(LYR):17.76

Loading ...

Bristol Myers Squibb Co. Stock Outperforms Competitors Despite Losses on the Day

Dow Jones
·
1 hour ago

BMY Terminates Early Leukemia Trial, Trimming One Risky Bet From Its Oncology Pipeline

TIPRANKS
·
6 hours ago

InflaRx Appoints Gabriela Alperovich as SVP, Global Head of Clinical Development

Reuters
·
Yesterday

Iovance Biotherapeutics Names Noah Berkowitz Chief Medical Officer

Reuters
·
Yesterday

Bristol Myers Squibb Deepens Commitment to Healthcare Professionals Through Champions in Care Movement

THOMSON REUTERS
·
Yesterday

Sanofi’s Regeneron Fix Requires Extra Shot of M&A

Reuters
·
Yesterday

Bayer Names Christoph Koenen Chief Medical Officer

Reuters
·
Yesterday

Faron Pharmaceuticals Doses First Patient in Phase 1/2 BLAZE Trial of Bexmarilimab Plus Bristol Myers’ Opdivo in PD-1-Resistant Solid Tumors

Reuters
·
Yesterday

U.S. Food and Drug Administration Approves Expanded Indication for Bristol Myers Squibb’s Camzyos® (Mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (Ohcm) in Adults and Pediatric Patients*

THOMSON REUTERS
·
Yesterday

Bristol-Myers Squibb's Camzyos to Treat Heart Condition Receives FDA Approval for Pediatric Patients

MT Newswires Live
·
Yesterday

FDA: Approved Camzyos (Mavacamten) Capsules as First Treatment for Children with Symptomatic Obstructive Hypertrophic Cardiomyopathy - Website

THOMSON REUTERS
·
Yesterday

FDA Approves First Drug to Improve Functional Capacity and Symptoms in Children with Rare Inherited Heart Condition

THOMSON REUTERS
·
Yesterday

FDA: Camzyos Carries Boxed Warning for Heart Failure Risk, Restricted to Rems Program

THOMSON REUTERS
·
Yesterday

FDA approves Bristol Myers’ Camzyos capsules for children with oHCM

TIPRANKS
·
Yesterday

Bristol-Myers' Protocol Changes Add Risk, Keep Admilparant on Track, UBS Says

MT Newswires Live
·
Yesterday

BMY Expands Real-World Cancer Data With New AUGTYRO Study in Korea

TIPRANKS
·
Yesterday

Pharma Sector Doubles Down on AI to Slash Costs, Timelines

Reuters
·
Sep 29

Helix BioPharma Names Karen Krumeich Board Chair, Adds Three Directors

Reuters
·
Sep 29

Bristol Myers Squibb Co. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Sep 29

US Drugmakers Turn to China for Licensing Deals

Reuters
·
Sep 28